Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics

Pharmacogenomics Journal

Volumn 12, Issue 1, 2012, Pages 54-61

  Liou, Y J ^a,b   Bai, Y M ^a,b   Lin, E ^c,d   Chen, J Y ^e   Chen, T T ^e   Hong, C J ^a,b   Tsai, S J ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c VITA GENOMICS INC   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e YULI VETERANS HOSPITAL   (Taiwan)

Author keywords

antipsychotic; gene gene interaction; insulin induced gene 1; insulin induced gene 2; metabolic syndrome

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; INSIG1 GENE; INSIG2 GENE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 85027939301     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.74     Document Type: Article

References (28)

1. DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8: 15-22.
2. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119: 4-14.
3. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68(Suppl 4): 8-13. (Pubitemid 46762118)
4. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295-303.
5. Medved V, Kuzman MR, Jovanovic N, Grubisin J, Kuzman T. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. J Psychopharmacol 2009; 23: 915-922.
6. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008; 10: 788-797.
7. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91-100. (Pubitemid 44881290)
8. Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009; 111: 1-8.
9. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163: 1273-1276. (Pubitemid 44464457)
10. Tsai SJ, Hong CJ. Pharmacogenetic studies of psychotropic druginduced adverse effects. Current Pharmacogenomics 2005; 3: 157-164.
11. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 338-343. (Pubitemid 47075503)
12. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009; 29: 16-20.
13. Ellingrod VL, Miller del D, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008; 98: 47-54. (Pubitemid 350235903)
14. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110: 489-500. (Pubitemid 35232292)
15. Yabe D, Brown MS, Goldstein JL. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory elementbinding proteins. Proc Natl Acad Sci USA 2002; 99: 12753-12758.
16. Cervino AC, Li G, Edwards S, Zhu J, Laurie C, Tokiwa G et al. Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics 2005; 86: 505-517. (Pubitemid 41416784)
17. Liu JP. New functions of cholesterol binding proteins. Mol Cell Endocrinol 2009; 303: 1-6.
18. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T et al. A common genetic variant is associated with adult and childhood obesity. Science 2006; 312: 279-283.
19. Skelly T, Pinheiro AP, Lange LA, Sullivan PF. Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia? Mol Psychiatry 2007; 12: 321-322. (Pubitemid 46496837)
20. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-r-lated metabolic adverse effects? Mol Psychiatry 2009; 14: 308-317.
21. Lou XY, Chen GB, Yan L, Ma MJZ, Zhu J, Elston RC et al. A g neralized combinatorial approach for retecting gene-by-gene and geneby-environment i t-ractions withtapplication to nicotine d pendence. Am J Hum Genet 2007; 80: 1125-1137.
22. American Psychiatric Association 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Association: Washington, DC.
23. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008; 66: 87-98. (Pubitemid 351482562)
24. Storey JD. A direct approach to false discovery rate. J R Statist Soc B 2002; 64: 479.
25. Fernø J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 2005; 5: 298-304. (Pubitemid 41486229)
26. Raeder MB, Fernø J, Vik-Mo AO, Steen VM. SREBP activation by antipsychotic-and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 2006; 289: 167-173. (Pubitemid 44322486)
27. Fernø J, Vik-Mo AO, Jassim G, Hävik B, Berge K, Skrede S et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009; 203: 73-84.
28. Engelking LJ, Liang G, Hammer RE, Takaishi K, Kuriyama H, Evers BM et al. Schoenheimer effect explained-feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest 2005; 115: 2489-2498. (Pubitemid 41266211)